mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer
Authors:
- Anju KumariAKAnju Kumari
- Lisa GesumariaLGLisa Gesumaria
- Yan-Jin LiuYLYan-Jin Liu
- V. Keith HughittVHV. Keith Hughitt
- Xiaohu ZhangXZXiaohu Zhang
- Michele CeribelliMCMichele Ceribelli
- Kelli M. WilsonKWKelli M. Wilson
- Carleen Klumpp-ThomasCKCarleen Klumpp-Thomas
- Lu ChenLCLu Chen
- Zina ItkinZIZina Itkin
- Craig J. ThomasCTCraig J. Thomas
Open Access
- 8 March 2023
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (5)
Abstract
Small cell lung cancer (SCLC) is a recalcitrant malignancy with limited treatment options. Bromodomain and extraterminal domain inhibitors (BETis) have shown promising preclinical activity in SCLC, but the broad sensitivity spectrum limits their clinical prospects. Here, we performed unbiased high-throughput drug combination screens to identify therapeutics that could augment the antitumor activities of BETis in SCLC. We found that multiple drugs targeting the PI-3K–AKT–mTOR pathway synergize with BETis, among which mTOR inhibitors (mTORis) show the highest synergy. Using various molecular subtypes of the xenograft models derived from patients with SCLC, we confirmed that mTOR inhibition potentiates the antitumor activities of BETis in vivo without substantially increasing toxicity. Furthermore, BETis induce apoptosis in both in vitro and in vivo SCLC models, and this antitumor effect is further amplified by combining mTOR inhibition. Mechanistically, BETis induce apoptosis in SCLC by activating the intrinsic apoptotic pathway. However, BET inhibition leads to RSK3 upregulation, which promotes survival by activating the TSC2-mTOR-p70S6K1-BAD cascade. mTORis block this protective signaling and augment the apoptosis induced by BET inhibition. Our findings reveal a critical role of RSK3 induction in tumor survival upon BET inhibition and warrant further evaluation of the combination of mTORis and BETis in patients with SCLC.Keywords
All Related Versions
Funding Information
- Instituto Nacional de Cancerología (BC011839,BC011787)
This publication has 54 references indexed in Scilit:
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT SignalingCancer Discovery, 2011
- Increased Insulin-Like Growth Factor 1 Receptor Protein Expression and Gene Copy Number in Small Cell Lung CancerJournal of Thoracic Oncology, 2010
- Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung CancerClinical Cancer Research, 2010
- Selective inhibition of BET bromodomainsNature, 2010
- Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung CancerCancer Research, 2008
- Chemical combination effects predict connectivity in biological systemsMolecular Systems Biology, 2007
- mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates AktCancer Research, 2006
- Phosphorylation and Functional Inactivation of TSC2 by ErkCell, 2005
- Transient Expression of Wild-type or Mitochondrially Targeted Bcl-2 Induces Apoptosis, whereas Transient Expression of Endoplasmic Reticulum-targeted Bcl-2 Is Protective against Bax-induced Cell DeathJournal of Biological Chemistry, 2001
- LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processingThe EMBO Journal, 2000